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Detailed analyses of the 5500 genes revealed by the complete Plasmodium genome 
sequence are yielding new candidate parasite antigens and strategies that may contribute 
to a successful vaccine against malaria in the coming decade.In the mid-1980s researchers con-
fidently predicted that an effective 
vaccine against Plasmodium falci-
parum, the most dangerous species 
of malaria parasite, would be avail-
able within a decade. Twenty years 
later, although a number of clinical 
and field trials of various malaria vac-
cines have taken place or are ongo-
ing, the promise of an effective vac-
cine—even as an adjunct measure to 
accompany insecticide-treated bed 
nets and mosquito control—is as 
distant as ever. This Essay summa-
rizes some of the difficulties that sci-
entists face in developing a vaccine 
against one of the greatest scourges 
of the developing world, surveys pre-
vious and ongoing vaccine efforts, 
and discusses future directions that 
will be influenced by the availability 
of the full genome sequence of P. 
 falciparum (Gardner et al., 2002).
Obstacles to a Malaria Vaccine
Estimates of the annual death toll 
due to malaria infection vary, but all 
indicate that this is a devastating 
and underestimated disease affect-
ing the tropical regions of the world 
that may kill as many as 2.5 million 
people annually (Snow et al., 2005). 
Furthermore, the impact of malaria 
on the global economy should not be 
overlooked. The 2004 Copenhagen 
Consensus of expert economists 
(http://www.copenhagenconsen-
sus.com/Default.aspx) concluded 
that effective malaria control ranked 
number 4 on the list of measures that 
would favorably impact the world 
economy. One route to address the 
huge burden imposed by malaria on 
the developing world is vaccination. 
However, many obstacles have to be surmounted to create a vaccine 
capable of protecting against this 
complex pathogen.
Chief among these are the follow-
ing. (1) The life cycle of the parasite 
is extremely intricate—at different 
stages of its life cycle, the Plasmo-
dium parasite presents complex 
immunologically distinct surfaces to 
the host immune system (see Figure 
1). Thus, any vaccine consisting of a 
single protein component needs to 
invoke innate and adaptive immune 
responses and immunological mem-
ory. (2) The blood stage of Plasmo-
dium causes the many pathologi-
cal manifestations associated with 
malaria infection, and thus proteins 
expressed during this stage should 
include good candidate compo-
nents for a vaccine. However, while 
resident in host erythrocytes, P. fal-
ciparum undergoes antigenic varia-
tion. The principal parasite protein 
and virulence factor expressed on 
the surface of host erythrocytes 
known to undergo antigenic varia-
tion is PfEMP1. This multimodular 
adhesin protein is encoded by 50–60 
var genes, as revealed by the com-
plete Plasmodium genome sequence 
(Gardner et al., 2002). It is responsi-
ble for parasite sequestration in deep 
tissue vasculature through binding 
to endothelial surface proteins. The 
var genes are expressed in a clonal 
fashion, but the expressed gene 
may switch in any given individual 
parasite, and the individual PfEMP1 
adhesin modules (known as DBL 
and CIDR) mediate sequestration 
and have unique binding specifici-
ties. Therefore, the adhesion profile 
of the parasite and resulting pathol-
ogy depends upon the specificities Cell 124, Febof the constituent DBL and CIDR 
domains of the expressed var gene 
and the distribution of the target 
host receptors. Typical sequestra-
tion-associated pathologies involve 
the brain (cerebral malaria) and 
the placenta (pregnancy associ-
ated malaria, PAM). Vaccination to 
prevent sequestration in the host 
vasculature would aim to gener-
ate antibodies that would prevent 
the parasite ligand-host receptor 
interaction. Although potentially 
desirable, it is probably not possi-
ble to immunize humans effectively 
against all of the potential >250 
adhesin domains of PfEMP1, espe-
cially as there is an enhanced rate of 
recombination among var genes. (3) 
The third obstacle is lack of corre-
lates of immune protection. It is not 
completely clear what type of immu-
nological response would be effec-
tive against the malaria parasite. 
Most likely protection will involve a 
combination of antibody- and cell-
mediated immune responses. For 
example, it is well-established that 
antibodies of clinically immune indi-
viduals alone can prevent parasite 
proliferation in host red blood cells 
(Cohen and Butcher, 1970), and that 
protection against the sporozoite 
stage involves both antibody- and 
cell-mediated immunity. Repeated 
and prolonged exposure to malaria 
parasites invokes immunity but it 
is not sterilizing, that is, it does not 
eradicate all parasites and does not 
provide complete protection against 
future challenge. Therefore, this 
type of immunity should be consid-
ered preimmunity, particularly as it is 
short-lived and memory T cells are 
not appropriately engaged.ruary 24, 2006 ©2006 Elsevier Inc. 689
Figure 1. Four Strategies for Developing 
a Vaccine against Malaria
(1) Pre-erythrocytic vaccination aims to pre-
vent entry of sporozoites into host liver cells 
(hepatocytes) and their subsequent develop-
ment to liver schizonts. Blocking of invasion 
may be achieved with antibodies and abro-
gation of development by cell-mediated im-
munity. The biggest drawback is that a single 
sporozoite escaping attenuation may cause 
a fully pathogenic blood stage infection. This 
happened in clinical trials of the latest anti-
sporozoite vaccine called RTS,S (Alonso et 
al., 2005). (2) Erythrocytic vaccination targets 
the life-cycle stage that invades and devel-
ops in host erythrocytes, which is associated 
with disease pathology. Vaccination to block 
parasite development in host red blood cells 
depends on generating antibodies to prevent 
erythrocyte invasion by merozoites released 
from schizonts (of liver or blood origin). Anti-
bodies target key merozoite surface proteins 
(such as MSP-1) or those contained in spe-
cialized organelles associated with invasion 
(such as AMA-1). The biggest drawback is the 
limited window of opportunity that exists to 
prevent merozoite invasion of the erythrocyte 
(merozoites are only outside erythrocytes for 
less than 2 min) and the fact that P. falciparum 
uses alternative invasion pathways. (3) Trans-
mission-blocking vaccination seeks to stimu-
late the production of antibodies that prevent 
either fertilization of the gametes in the blood 
meal taken into the mosquito midgut or the 
development of the zygote to an ookinete and 
its successful invasion of the mosquito mid-
gut wall. The biggest drawback is that this 
strategy is altruistic, providing a herd benefit 
by protecting future victims from the mosqui-
to’s bite. (4) The fourth strategy, anti-disease 
vaccination, aims for example to block the se-
questration of parasite-infected erythrocytes 
(which causes much of the serious pathology 
of malaria) by preventing the parasite surface 
protein PfEMP1 from interacting with various vascular endothelial cell-surface receptors. A successful vaccine that is not based upon attenuating 
the whole parasite is likely to contain components of the first three categories. Anti-disease vaccination may be of use alone but would also be a 
desirable addition to a polyvalent, multicomponent vaccine formulation.Current Strategies for Vaccine 
Development
So should a vaccine against malaria 
attempt to achieve sterilizing immu-
nity or should its goal be to prevent 
malaria-associated pathology (such 
as cerebral malaria or pregnancy-
associated malaria), termed an anti-
disease approach? Pregnancy-asso-
ciated malaria in particular lends itself 
to this approach because adherence 
of the parasite-infected erythrocytes 
to endothelial cells of the placenta is 
known to be due to the interaction of 
largely one DBL domain of PfEMP1 
(DBL3-γ subunit of VAR2CSA) with 
the placenta-specific sugar chon-
droitin sulfate A. Thus, immunization 
with DBL3-γ should induce antibodies 
that would block binding of PfEMP1 690 Cell 124, February 24, 2006 ©2006 Ecarrying this domain to the placenta 
(Viebig et al., 2005). Immunization to 
control disease, although currently 
focused on individual pathologies, 
would more closely resemble the 
natural nonsterilizing immunity that 
develops in people in sub-Saharan 
Africa who are constantly exposed to 
the Plasmodium parasite.
There are many vaccine candidates 
and strategies for inducing immunity 
against malaria parasites already 
under consideration (reviewed in 
Targett, 2005); summarized at http://
www.who.int /vaccine_research /
documents/en/malaria_table.pdf; for 
a review of human trials see Graves 
and Gelbland, 2006). The vast major-
ity of these have a common theme in 
that they attempt to use a single or lsevier Inc.limited number of recombinant par-
asite products (mainly “antigens”) 
to induce immunity. Besides immu-
nization to diminish the disease, 
vaccination may seek to control 
parasite proliferation and survival. In 
the latter, parasite invasion of host 
cells may be blocked and parasite 
numbers reduced at three different 
stages of the life cycle: pre-erythro-
cytic, erythrocytic, and development 
in the mosquito vector (see Figure 
1). However, there are drawbacks to 
targeting each individual stage (see 
legend to Figure 1).
Although true correlates of immune 
protection in the host against malaria 
infection are absent, both antibody 
and cell-mediated immunity (both 
CD4+ and CD8+ T cell responses) are 
required. A number of different vac-
cination strategies to generate such 
responses from single or more likely 
a combination of candidate antigens 
from different life-cycle stages are 
underway. The most promising strat-
egy appears to be a heterologous 
prime-boost approach in which prim-
ing of the immune response to cho-
sen antigens is achieved using DNA 
expression vectors (plasmid or atten-
uated viral vectors, AVV) followed 
by boosting using AVV expressing 
the same antigens (reviewed in Tar-
gett, 2005). In total there are about 
50 vaccine candidates against P. 
falciparum that are currently under 
development (http://www.who.int/
vaccine_research/documents/en/
malaria_table.pdf), and all pre-date 
publication of the complete genome 
sequence of Plasmodium. Investment 
in pipelines for malaria vaccine devel-
opment has been relatively poor, and 
although strategies for certain candi-
dates may have been abandoned, all 
50 vaccine candidates remain in the 
framework for continued develop-
ment. But the complexity of the para-
site and the problem of the lack of 
true correlates of disease are coming 
back to haunt researchers. Although 
all candidates were chosen on the 
basis of their ability to elicit some 
form of inhibitory immune response 
against the parasite (as measured in 
vitro and, for some, in animal models), 
there is little further basis for rational 
vaccine design. Obviously, it would 
be prohibitively expensive to take the 
existing 50 candidates through full 
multiphase clinical trial evaluation. 
Without new investment and dropping 
some of the current candidates, it is 
hard to see how funds can be made 
available for the further development 
of any new candidate vaccines that 
might be uncovered by Plasmodium 
genome and post-genome research. 
Such decisions perhaps represent 
one of the community’s greatest cur-
rent challenges.
Vaccine Research in the Post-
Genome Era
What have P. falciparum genome and 
post-genome analyses provided in 
the way of new vaccine candidates? The genomics approach has been 
helped substantially by comparative 
data from genome characterization 
and post-genome studies of other 
species of malaria parasites, most 
notably those of rodents. These 
rodent malaria parasites—principally 
Plasmodium berghei, Plasmodium 
yoelii, and Plasmodium chabaudi—
serve as useful models for the entire 
parasite life cycle and for interac-
tions among the host, the parasite, 
and its insect vector, the mosquito. 
Each rodent Plasmodium species is 
thought to share with P. falciparum 
a core of 4500 genes (of a total 
genome complement of 5300 to 5500 
genes). These shared genes include 
orthologs of many of the leading 
human parasite vaccine candidates 
(Hall et al., 2005). In the research 
community’s Plasmodium genome 
database—PlasmoDB (www.plasmo 
db.org)—over 10% (579 of ?5500) 
of annotated P. falciparum genes 
are predicted to encode proteins 
containing signal peptides. These 
proteins enter the parasite endoplas-
mic reticulum and are transported to 
the parasite surface, or the surface 
of the occupied host erythrocyte, or 
to parasite organelles (such as the 
rhoptries, micronemes, and dense 
granules required for invasion of new 
host erythrocytes).
Of these proteins, transcriptome 
and proteome data indicate that only 
197 are expressed in the life-cycle 
stages targeted for vaccine develop-
ment: 43 (32) proteins are expressed 
in gametocytes, 57 (42) are sporo-
zoite specific, and 94 (61) proteins 
are uniquely expressed in either the 
young or late schizont or merozoite 
stages (numbers in parentheses 
indicate the number of orthologs 
found in P. berghei). In principle, 
each one of the surface proteins 
might be a vaccine candidate if the 
vaccine strategy aims to stimulate 
the production of antibodies that 
might interfere with the function of 
that protein. Additional post-genome 
analyses have pinpointed poten-
tial candidate proteins from these 
groups that are associated with sur-
face/rhoptry transport structures 
called Maurer’s clefts in the parasite-Cell 124, Febinfected erythrocytes (Sam-Yellowe 
et al., 2004; Vincensini et al., 2005), 
or with schizont/merozoite lipid rafts 
enriched with GPI-anchored pro-
teins (Sanders et al., 2005). Finally, 
genome and post-genome compari-
sons have been exploited to identify 
genes that contain a signal peptide, 
are expressed in the blood stage, 
and are undergoing accelerated evo-
lution (106 in total), which indicates 
a response to selective pressure 
such as recognition by the immune 
system, a property that is arguably 
desirable in a vaccine candidate (Hall 
et al., 2005).
Post-genome analyses have also 
provided fresh insights into existing 
vaccine candidates. For example, the 
AMA-1 protein—which is released 
from micronemes to the surface of 
the invasive merozoite after sch-
izont rupture—has been a leading 
blood-stage vaccine candidate. Both 
monoclonal and polyclonal antibod-
ies against AMA-1 block erythrocyte 
invasion in vitro, and there is good 
evidence in animal models for AMA-
1’s efficacy as a vaccine candidate 
(Deans et al., 1988; Crewther et al., 
1996). Both proteome and transcrip-
tome analyses (LeRoch et al., 2003) 
indicate that AMA-1 is expressed not 
only in merozoites but also in sporo-
zoites, stimulating research demon-
strating that those AMA-1-specific 
antibodies that prevent erythrocyte 
invasion also prevent sporozoite 
infection of hepatocytes (Silvie et al., 
2004). Therefore, AMA-1 may be a 
pre-erythrocytic as well as a blood-
stage vaccine candidate.
The global gene analyses empha-
size the iterative nature of certain 
aspects of the parasite life cycle, 
including invasion (LeRoch et al., 
2003; Hall et al., 2005; Florens et 
al., 2002). Both sporozoites and 
merozoites possess the same com-
plement of invasion-associated 
organelles, and there is overlap with 
the ookinete stage in the mosquito, 
which, however, lacks rhoptries (see 
Figure 1, and review article by Cow-
man and Crabb in this issue of Cell). 
There may be many invasion proteins 
shared by merozoites and sporo-
zoites and thus more multistage vac-ruary 24, 2006 ©2006 Elsevier Inc. 691
cine candidates can be proposed. 
One such multistage vaccine candi-
date is MAEBL, which is essential for 
invasion of mosquito salivary glands 
by sporozoites (Kariu et al., 2002). 
MAEBL shares a similar expres-
sion pattern to AMA-1 and is a curi-
ous hybrid of AMA-1 domains and 
domains called erythrocyte binding 
ligands. Indeed detailed, independ-
ent transcriptome analyses suggest 
that many genes encoding proteins 
that are critical for key events (such 
as invasion of host or insect cells) are 
expressed at multiple points in the 
parasite life cycle.
Post-genome research aided 
greatly by genetic manipulation of 
Plasmodium has provided insights 
into the biology of the parasite and its 
interactions with both host and vec-
tor, which will have implications for 
vaccine development. For example, 
functional redundancy among para-
site vaccine candidates—such as the 
P28/P25 family of ookinete surface 
proteins that are leading transmis-
sion blocking candidates for both 
P. vivax and P. falciparum—cautions 
against the use of a single protein in 
vaccine formulations. A single pro-
tein may provide sufficient selective 
pressure to generate mutations (or 
sequence loss) in the target gene 
and the proteins encoded by other 
closely related genes may take up 
the functional slack resulting in para-
sites that are immune to antibodies 
generated by a single protein vaccine 
(Tomas et al., 2001). Furthermore, the 
demonstration that P. falciparum can 
exploit mechanistically distinct path-
ways for the invasion of the human 
erythrocyte will also affect blood-
stage vaccine formulations (Stubbs 
et al., 2005).
A New Twist to an Old Strategy
One very striking post-genome 
development is a new twist on an old 
but proven strategy: a vaccine com-
posed of a live-attenuated whole 
organism. Many studies have shown 
that vaccination with an attenuated 
whole parasite generates effec-
tive and (in some cases) long-last-
ing protection in man against both 
sporozoites (Clyde et al., 1973) and 692 Cell 124, February 24, 2006 ©2006 Easexual blood stages. In the case of 
sporozoite vaccination, the parasite 
is attenuated by irradiation of the live, 
infected mosquito and administered 
either through a mosquito bite or by 
injection of the sporozoites after they 
have been purified from the irradiated 
mosquito. Unfortunately, such a vac-
cine has a number of drawbacks, not 
the least of which is how to scale up 
generation of attenuated sporozoites 
to meet global demand requiring the 
vaccination of many millions of indi-
viduals. However, there are attempts 
to address this problem as well 
as the logistics of how to store the 
attenuated parasites for global distri-
bution (http://www.Sanaria.com). An 
additional production-line problem 
is the potential inconsistency of the 
product: effective irradiation of the 
sporozoites is absolutely critical to 
generate an efficacious vaccine. Too 
little irradiation and the sporozoite 
will remain infectious and generate a 
full-blown malaria infection in “vac-
cinated” subjects; but too much irra-
diation will kill the parasite, and dead 
parasites do not generate effective 
immunity. Immunity is dependent 
upon the ability of the sporozoite 
to traverse Kupffer cells of the liver 
and to initiate an aborted pattern of 
development in hepatocytes. Thus, 
immunization with a radiation-atten-
uated sporozoite carries risks.
An alternative might be a geneti-
cally attenuated sporozoite . In two 
independent studies, three genes 
have been identified that are exclu-
sively expressed in the sporozoite 
(all studies have been performed in 
P. berghei) and that when disrupted 
give rise to a parasite that is unable 
to infect mice. The genes are called 
UIS3, UIS4 (Mueller et al., 2005), and 
P36p (van Dijk et al., 2005), and all 
of them have homologs in P. falci-
parum. Sporozoites carrying muta-
tions in these genes are motile, retain 
the ability to invade hepatocytes in 
vitro, and are able to form a parasi-
tophorous vacuole (an early post-
invasion event). However, the mutant 
parasites do not develop fully in the 
infected hepatocyte and instead dis-
appear after 12 hr in culture. This indi-
cates that the mutant parasite unlike lsevier Inc.its wild-type counterpart may fail to 
suppress apoptosis of the infected 
host cell, and indeed this seems 
to be the case for P36p. Examina-
tion of the immunogenicity of these 
mutant parasites has provided the 
most promising data for UIS3 and 
P36p. Both forms of mutant parasite, 
when used as an immunogen, gave 
full protection to subsequent chal-
lenge with wild-type parasites in two 
strains of mice, including one that is 
highly susceptible to infection. It is 
possible that the failure to suppress 
apoptosis by the genetically attenu-
ated sporozoites actually stimulates 
immunogenicity and potentiates the 
immune response leading to the gen-
eration of protective immunity.
Two challenges must now be met: 
(1) Characterization of the target 
sporozoite antigens and the effector 
arms of the immune system that pro-
vide protection; (2) The generation 
and characterization of equivalent 
mutant sporozoites in P. falciparum. 
Also, the precise functions of the UIS 
proteins and P36p need to be elu-
cidated. It is known that UIS4 binds 
to host apolipoprotein A1 (ApoA1) 
recruiting it to the host-parasite inter-
face where it recruits sufficient cho-
lesterol for development of the para-
sitophorous vacuole. In keeping with 
this hypothesis, the amount of avail-
able ApoA1 regulates the number 
of mature liver stage parasites that 
develop, and a mouse strain deficient 
in ApoA1 is completely refractory 
to P. berghei infection. Increasing 
knowledge about the protein-protein 
interactions between host and para-
site offers new avenues for antipara-
sitic strategies.
Genome and post-genome 
research is providing a treasure 
trove of potential candidate proteins 
for a malaria vaccine. The current 
challenge is to provide further vali-
dation of these proteins such that 
they might enter a pipeline for vac-
cine development in a rational fash-
ion. Post-genome research can help 
to rank candidates based upon an 
agreed set of criteria, for example, 
the essential nature of the protein 
and its potential partners in protein-
protein complexes. Yet, however 
promising the pipeline may sound 
it is a long and difficult process to 
develop an effective malaria vaccine, 
and the parasite is far from posing 
as a sitting target. In a perfect sce-
nario one could perhaps envisage 
a malaria vaccine within a decade, 
but the history of malaria vaccine 
research should teach us that the 
nefarious malaria parasite will con-
tinue to dodge our greatest efforts.
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